Loading company
Lexicon Pharmaceuticals, Inc.
LXRX · Nasdaq · ·
Next earnings: November 5, 2026
$1.89-0.3%Sep 29 close
- 1M
- -17.7%
- 6M
- +24.8%
- 1Y
- +39.6%
- 5Y
- -64.8%
LXRX · Nasdaq · ·
Next earnings: November 5, 2026
$1.89-0.3%Sep 29 close
Lexicon Pharmaceuticals, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $692K | $28.9M | -97.60% |
| Profit | -$31.8M | $3.3M | -1,077.09% |
| Profit per share | -$0.07 | $0.01 | -800.00% |
| Free Cash Flow | -$17.2M | -$48.8M | +64.68% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lexicon Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Lexicon Pharmaceuticals, Inc. has no earnings call transcript available.